Pharmacovigilance and Post-Black Market Surveillance

  title={Pharmacovigilance and Post-Black Market Surveillance},
  author={Nicolas Langlitz},
  journal={Social Studies of Science},
  pages={395 - 420}
  • Nicolas Langlitz
  • Published 2009
  • Medicine
  • Social Studies of Science
  • Pharmacovigilance can be defined as a set of practices aiming at the detection, understanding and assessment of risks related to the use of drugs in a population, and the prevention of consequential adverse effects. In a narrower sense, the term refers exclusively to postmarket surveillance. This paper briefly outlines how pharmacovigilance has come to play a central role in the regulation of novel pharmaceuticals. However, the focus of the text is on mechanisms emerging in an experimental drug… CONTINUE READING
    21 Citations

    Topics from this paper

    Incorporation of New Technologies into Global Pharmacovigilance
    • 10
    • PDF
    Rethinking Innovation Accounting in Pharmaceutical Regulation
    • 21
    • Highly Influenced
    The Vioxx® legacy: Enduring lessons from the not so distant past.
    • 3
    • PDF
    Guest editors’ introduction
    • PDF
    The Pharmacology of Distributed Experiment – User-generated Drug Innovation
    • 19
    Innovation for Safe and Effective Medical Devices
    • 3
    Educated Guesses and Other Ways to Address the Pharmacological Uncertainty of Designer Drugs
    • 11
    • PDF


    Postmarketing surveillance--lack of vigilance, lack of trust.
    • 109
    • PDF
    Linking Pharmacovigilance with Pharmacogenetics
    • 22
    • PDF
    Research methods in drug surveillance.
    • 24
    Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem
    • 96
    Testing times: the emergence of the practolol disaster and its challenge to British drug regulation in the modern period.
    • J. Abraham, Courtney Davis
    • Medicine
    • Social history of medicine : the journal of the Society for the Social History of Medicine
    • 2006
    • 32
    [Illicit market of controlled drugs in Italy: new drugs and trends].
    • S. Schiavone
    • Medicine
    • Annali dell'Istituto superiore di sanita
    • 2002
    • 3
    Failing the public health--rofecoxib, Merck, and the FDA.
    • E. Topol
    • Medicine
    • The New England journal of medicine
    • 2004
    • 579
    • PDF